News Merck and Pfizer stop third Bavencio ovarian cancer trial Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
News Cell Mogrify gets £420k funding for regenerative cell therap... UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes.
Partner Content Partner Content Immuno-Oncology 2018 News: MHRA Interview and New Speaker Im... Just Over 1 Week Until Immuno-Oncology 2018 Commences
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
